How to treat AL amyloidosis in 2020?

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, discusses treatment options for light chain (AL) amyloidosis, including how the results of the ANDROMEDA study (NCT03201965) evaluating daratumumab plus CyBorD may represent a new approach to patients with amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

• Catégorie